AVEO and Schering-Plough to Develop Anti-HGF Antibody

May 1, 2007
Oncology NEWS International, Oncology NEWS International Vol 16 No 5, Volume 16, Issue 5

AVEO and Schering-Plough to Develop Anti-HGF Antibody

CAMBRIDGE, Massachusetts—AVEO Pharmaceuticals, Inc. has entered into an exclusive worldwide agreement with Schering-Plough Corporation to develop and commercialize AV-299, a highly potent antagonist of hepatocyte growth factor/scatter factor (HGF/SF). The antibody has shown excellent efficacy in preclinical models of human cancer and is expected to enter clinical trials in early 2008, the companies announced in a press release.

Related Content:

Technology